Ranibizumab (Lucentis)
admin February 2nd, 2007
The FDA report and Genentech report on an ongoing study (SAILOR) which confirmed the higher incidence of stroke associated wtih ranibizumab with a 0.5 mg dose group compared to the 0.3 mg dose group (1.2% versus 0.3%, respectively; P=0.02) which used in patients with neovascular (wet) age-related macular degeneration who received intravitreal Lucentis.